Written and maintained by CASRAI Editorial Board
Published
On this page
Submitting an abstract to the American Society of Clinical Oncology (ASCO) Annual Meeting is a vital pathway for clinicians and translational researchers to present groundbreaking oncology data. Each year, thousands of submissions undergo peer review by ASCO Scientific Program Committee track leaders to curate plenary lectures, rapid oral sessions, clinical science symposia, and poster presentations. Navigating the submission portal demands strict compliance with character budgets, structured reporting formats, and author conflict-of-interest declarations.
Within academic oncology, an accepted ASCO abstract functions as a formal citable scientific contribution published in an annual supplement to the Journal of Clinical Oncology (JCO). Whether funded through institutional departmental awards or competitive NCI funding, research groups must ensure their investigations adhere to established ethical oversight and the International Committee of Medical Journal Editors (ICMJE authorship criteria) before finalizing their author roster.
Ask CASRAI · free to try
Ask about this guide — your first 2 questions are free.
Suggested question: “What is the character limit for an ASCO abstract submission?”
Purpose of the section
The abstract represents the definitive, standalone summary used by ASCO track reviewers to judge scientific merit, clinical relevance, and methodological rigor. Reviewers evaluate whether the study addresses an important clinical dilemma, applies sound biostatistical principles, and offers actionable findings that influence cancer biology or patient care. Because review committees evaluate dense volumes of submissions within narrow evaluation cycles, clarity and empirical precision are paramount.
Unlike a general review or preliminary research plan, an ASCO scientific abstract must report concrete, verifiable data. Statements indicating that “results are pending analysis” or “updated survival curves will be presented” frequently prompt disqualification from competitive oral presentation tracks. The accepted abstract establishes priority of discovery and serves as the baseline document that informs clinical discussion across the global oncology community.
Structure
Official ASCO submission regulations require abstracts to follow a standardized four-part IMRaD framework. Adhering to this structured format ensures that clinical reviewers can systematically evaluate trial design and statistical outcomes.
- Background: A succinct 2–3 sentence framing outlining the unmet clinical need, biological rationale, or therapeutic question addressed by the trial.
- Methods: A clear summary of the study design (e.g., randomized phase III, single-arm phase II, retrospective cohort), patient eligibility criteria, dosing schedules, primary/secondary endpoints, and statistical testing methodologies.
- Results: A detailed quantitative presentation of study findings. Authors must report actual numerical data, including patient accrual numbers, objective response rates (ORR), progression-free survival (PFS), overall survival (OS), hazard ratios (HR), and adverse event frequencies with corresponding confidence intervals and p-values.
- Conclusions: A direct summary of the clinical implications of the findings, stating how the data impact practice or define future investigational directions.
Character Limits and Portal Accounting
The ASCO online submission system enforces a strict character ceiling. Authors must budget text according to the following specifications:
| Element | System Allowance | Accounting Rules |
|---|---|---|
| Abstract Body | 2,000 characters maximum | Spaces are included in the character count across Background, Methods, Results, and Conclusions |
| Abstract Title | Excluded from body count | Subject to separate character ceiling; must avoid commercial brand names |
| Author String and Institutions | Excluded from body count | Input through individual portal fields; includes mandatory disclosure links |
| Tables | Permitted (1 table maximum) | Tables deduct from total character allowance; rows and columns must be formatted within portal parameters |
A short annotated example
The following model abstract demonstrates compliant structure, precise reporting of clinical trial endpoints, and adherence to character constraints.
Title: Phase II Study of Trastuzumab Deruxtecan Combined with Tucatinib in HER2-Positive Metastatic Colorectal Cancer
[Background] Patients with HER2-amplified metastatic colorectal cancer (mCRC) refractory to standard chemotherapy have limited therapeutic options. We evaluated the efficacy and safety of combining the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) with the oral HER2 tyrosine kinase inhibitor tucatinib in this population.
[Methods] In this multicenter, open-label phase II trial (NCT04567890), patients with HER2-positive (IHC 3+ or IHC 2+/ISH+) mCRC who progressed on prior oxaliplatin- and irinotecan-based therapy received T-DXd (5.4 mg/kg IV every 3 weeks) and tucatinib (300 mg orally twice daily). The primary endpoint was confirmed objective response rate (ORR) by RECIST v1.1 assessed by blinded independent central review. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and safety.
[Results] Forty-eight patients were enrolled (median age 59 years; 62% male). At a median follow-up of 14.2 months, confirmed ORR was 45.8% (95% CI, 31.4%–60.8%), including 3 complete responses and 19 partial responses. Median DOR was 9.4 months (95% CI, 6.8–12.3). Median PFS was 8.2 months (95% CI, 6.1–10.4). The most common grade ≥3 treatment-related adverse events were neutropenia (22.9%), anemia (14.6%), and elevated AST/ALT (8.3%). Adjudicated drug-related interstitial lung disease occurred in 3 patients (6.2%; all grade 1/2) with no fatal events.
[Conclusions] Dual HER2 targeting with T-DXd and tucatinib demonstrated robust anti-tumor activity and a manageable toxicity profile in pretreated HER2-positive mCRC, supporting further randomized phase III investigation.
Annotation: This text contains approximately 1,620 characters (including spaces), remaining safely within the 2,000-character ceiling. It clearly specifies clinical trial registration (NCT number), sample size, primary and secondary endpoint data with 95% confidence intervals, and explicit safety frequencies.
Common mistakes
Authors submitting to ASCO frequently encounter administrative rejection or poor scoring due to predictable submission errors:
- Use of Proprietary Drug Names: Submitting trade names rather than generic chemical designations. ASCO policies require generic nomenclature; trade names in the title or body can result in disqualification.
- Premature Submissions Lacking Data: Submitting interim abstracts with phrases such as “final efficacy endpoints will be detailed in Chicago.” Except for specifically designated late-breaking placeholders, abstracts without tangible results are rejected.
- Sponsorship Failures: Neglecting to verify ASCO membership standing. If the presenting author is not an active ASCO member, an active member must formally sponsor the submission before the deadline.
- Misallocating Trial in Progress (TiP) Submissions: Submitting ongoing trials with preliminary data as standard abstracts rather than utilizing the designated TiP category, which is strictly reserved for study designs without preliminary efficacy or safety data.
- Co-Author Disclosure Gaps: Failing to ensure all co-authors complete mandatory financial disclosure forms prior to the final submission cutoff.
Checklist
Review and verify each procedural item before finalizing submission in the ASCO meeting system:
| Item | Action Required | Standard |
|---|---|---|
| 1. Membership & Sponsorship | Confirm first author membership or active ASCO sponsor approval | ASCO Active, Emeritus, or Fellow member in good standing |
| 2. Text Length Verification | Measure total body characters including spaces | ≤ 2,000 characters across all four sections |
| 3. Structural Architecture | Ensure exact presence of all 4 section headings | Background, Methods, Results, Conclusions |
| 4. Drug & Device Naming | Verify all compounds are named by generic terminology | No proprietary or trade brand designations |
| 5. Disclosures & COI | Confirm all co-authors submitted electronic disclosure records | Mandatory compliance for meeting presentation |
| 6. Submission Processing Fee | Remit nonrefundable abstract submission fee | $60 USD per abstract |
| 7. Presentation Commitment | Confirm presenter will register and attend in person | Mandatory registration; failure to present causes formal withdrawal |
Discipline differences
Abstract submission in clinical oncology differs significantly from submissions in basic biology or physical sciences:
- Late-Breaking Clinical Trial Placeholders: Clinical oncology relies on high-impact late-breaking abstracts (LBA) for phase III trials whose primary endpoints mature weeks before the conference. Authors submit placeholders outlining trial design, with final survival data submitted during a designated late-breaking window.
- Trials in Progress (TiP) Category: Oncology provides dedicated TiP poster sessions to introduce active clinical protocols to the oncology community. Unlike standard abstracts, TiP submissions prohibit preliminary outcome data to maintain trial integrity.
- Stringent Public Embargo Policies: Because ASCO presentations directly impact clinical practice and pharmaceutical market valuations, abstract contents remain under strict embargo until official release, with LBAs confidential until presentation day.
FAQ
What is the character limit for an ASCO abstract submission?
The ASCO Annual Meeting restricts the abstract body to a maximum of 2,000 characters, including spaces. This limit covers the Background, Methods, Results, and Conclusions sections. Title and author lists are budgeted separately.
Can non-members submit an abstract to ASCO?
Yes. Non-members may submit and present an abstract, provided that an active ASCO member in good standing agrees to sponsor the abstract within the submission portal.
Are tables permitted in an ASCO abstract submission?
Yes, authors may include one table in an abstract. However, the table reduces the overall character allowance according to system guidelines.
What is the difference between an ASCO regular abstract and a late-breaking abstract?
Regular abstracts must contain completed data by the regular February submission deadline. Late-breaking abstracts are reserved for randomized phase III trials or pivotal phase II trials where primary endpoint data maturity was biologically impossible by the initial deadline.
What happens if a co-author does not submit a disclosure form?
ASCO enforces mandatory conflict-of-interest disclosures for all authors. Incomplete author disclosures can delay processing or prevent final acceptance of the abstract.
Sources
- American Society of Clinical Oncology (ASCO). (2026). ASCO Annual Meeting Abstract Policies and Submission Requirements. Retrieved November 8, 2026, from https://www.asco.org/annual-meeting/abstracts-presentations/submission-details
- American Society of Clinical Oncology (ASCO). (2026). ASCO Annual Meeting Abstract Embargo and Confidentiality Policy. Retrieved November 8, 2026, from https://www.asco.org/annual-meeting/abstracts-presentations/abstract-policies-embargoes-exceptions/faqs
